



1651


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	van Oers, et al.	Examiner:	Unassigned
Serial No.:	10/620,090	Group Art Unit:	1651
Confirmation No.:	7405	Docket:	294-165
Filed:	July 15, 2003	Dated:	October 8, 2003
For:	DETECTION OF PRION DISEASE		

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:, Commissioner
for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450
on October 8, 2003*

Signed: **CLAIM FOR PRIORITY AND TRANSMITTAL
OF CERTIFIED COPY OF PRIORITY DOCUMENT**

Sir:


Applicants hereby claim priority under 35 U.S.C. § 119 based on European Patent Office Application No. 02077910.4 filed July 17, 2002.

The claim of priority to the above-referenced European Patent Office application has also been set forth in the Combined Declaration and Power of Attorney which is being filed concurrently herewith.

A certified copy of the priority document is submitted herewith.

The Commissioner is hereby authorized to charge any fees or additional fees associated with this communication to our Deposit Account No. 08-2461. A duplicate copy of this sheet is being submitted for that purpose.

Respectfully submitted,



Edna I. Gergel, Ph.D.
Registration No.: 50,819
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG:jlw
179497_1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	van Oers, et al.	Examiner:	Unassigned
Serial No.:	10/620,090	Group Art Unit:	1651
Confirmation No.:	7405	Docket:	294-165
Filed:	July 15, 2003	Dated:	October 8, 2003
For:	DETECTION OF PRION DISEASE		

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:, Commissioner
for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450
on October 8, 2003*

Signed: *Julie L. Watts*

**CLAIM FOR PRIORITY AND TRANSMITTAL
OF CERTIFIED COPY OF PRIORITY DOCUMENT**

Sir:

Applicants hereby claim priority under 35 U.S.C. § 119 based on European Patent Office Application No. 02077910.4 filed July 17, 2002.

The claim of priority to the above-referenced European Patent Office application has also been set forth in the Combined Declaration and Power of Attorney which is being filed concurrently herewith.

A certified copy of the priority document is submitted herewith.

The Commissioner is hereby authorized to charge any fees or additional fees associated with this communication to our Deposit Account No. 08-2461. A duplicate copy of this sheet is being submitted for that purpose.

Respectfully submitted,

Edna I. Gergel
Edna I. Gergel, Ph.D.
Registration No.: 50,819
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG:jlw
179497_1



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02077910.4

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 02077910.4
Demande no:

Anmeldetag:
Date of filing: 17.07.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

PEPSKAN SYSTEMS B.V.
Edelhertweg 15
8219 PH Lelystad
PAYS-BAS
Stichting Sanquin Bloedvoorziening
Plesmanlaan 125
1066 CX Amsterdam
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Detection of prion disease

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

G01N33/48

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

P57843EP00

(83)

Title: Detection of prion disease

5 This invention relates to the field of the detection of prion diseases. These diseases, also called transmissible spongiform encephalopathies (TSE), include bovine spongiform encephalopathy (BSE) or mad cow disease in cattle, scrapie in sheep, and Creutzfeldt-Jakob Disease (CJD) in man. Prion diseases are infectious diseases, generally transmitted by a conformer of the naturally present prion protein (PrP), though cases
10 may also occur spontaneously or from a genetic predisposition. Diagnosis of TSE typically requires demonstration of this conformer in animal or human brain.

 Prion diseases or TSE are a group of fatal non-inflammatory neurodegenerative disorders exemplified by BSE in cattle, scrapie in sheep, CJD in man.¹ TSE are characterised by a relatively long incubation period (e.g. >10 years in human), and
15 typically share accumulation of PrP^{Sc} in brain and in some cases also in lymphoid tissues.^{2, 3}

 The prion protein is an endogenous protein, that under normal conditions is also expressed in the brain, and also in various other tissues. This normal cellular prion protein (PrP^C) and PrP^{Sc} are different conformations of the same protein. Moreover PrP^C
20 and PrP^{Sc} differ in some physico-chemical and biochemical properties: PrP^C is soluble, exist in a non-aggregated form, and is sensitive to degradation by proteases, whereas PrP^{Sc} is insoluble, exist in an aggregated form, and is relatively resistant to degradation by proteases.⁴ It is hypothesised that a direct protein-protein contact between PrP^{Sc} and PrP^C generates a conformational change of PrP^C into PrP^{Sc}. Ultimately PrP^{Sc} forms
25 aggregates and accumulates in brain. At the final stage of the disease neurodegenerative changes occur in the brain, associated with severe neurological dysfunction, and ultimately death.

 The PrP gene of various animal species has been cloned and sequenced.⁵ The protein is encoded within a single exon, and consists of a long N-terminal signal sequence
30 followed by about 250 amino acid (AA) residues. The C-terminus contains a sequence of about 22 residues encoding for linker site for a glycosyl-phosphatidylinositol anchor, a property shared with many other membrane proteins. Furthermore, the protein contains

one disulfide bridge and two potential Asparagine-glycosylation sites. The sequence of the protein is well conserved among various animal species. Though differences in the secondary structure of PrP^{Sc} and that of PrP^C have been identified, the structural basis for the enhanced aggregatibility and proteolytic resistance of PrP^{Sc} as compared to those of PrP^C is still not resolved. In addition, the molecular basis for the existence of different strains of PrP^{Sc}, i.e. prions with different incubation times, is lacking, though it is assumed that these strains likely represent PrP^{Sc} with subtle differences in conformation.⁶

Crucial for the diagnosis of TSE is detection of PrP^{Sc} in brain, using e.g. immunohistochemistry or Western blotting. Detection of PrP^{Sc} in a more easily accessible sample, preferably blood, would also add to the diagnosis of TSE. However there is only very incomplete data available suggesting that PrP^{Sc} is present in blood.^{7, 8} For the in vitro diagnostic methods, polyclonal and monoclonal antibodies are usually applied.^{9, 10} For example, monoclonal antibody 3F4 detects PrP from human, hamsters, and felines. Importantly, it does not react with PrP from any other mammalian species and can thus not be used for the diagnosis of BSE or scrapies. Antibody 3F4 is reactive to both native and denatured forms of PrP and recognizes both protease sensitive and protease resistant forms of PrP. Antibodies against prions described in the literature so far, do not discriminate between PrP^C and PrP^{Sc}, except for one which can only be used for immunoprecipitation and which is therefore not suitable for regular immunodiagnostics.¹¹

Because most antibodies bind indiscriminately to both conformers, the specificity of diagnostic methods is based on differences in resistance to proteinase K (PK) digestion, solubility, or degree of aggregation. The high background of PrP^C in general and in blood in particular, is challenging the specificity of all current immuno-diagnostics, especially in situations when PK digestions cannot be well controlled (e.g. plasma samples, because plasma contains high concentrations of various protease inhibitors).¹²

The invention provides the insight that detectable neo-epitopes are exposed on a part of a protease-digested aberrant conformer (PrP^{Sc}) of a prion protein, such as on scrapie-associated prion protein, and provides the preparation of antibodies against these

epitopes and use of such antibodies in diagnostic tests. Such use is in particularly advantageous because it allows a better distinction between aberrant and non-aberrant conformers. The invention provides an antibody (herein also defined as a specific binding molecule or (poly)peptide with antibody properties, such as a single-chain antibody
5 fragment or other molecule provided with a specific complementarity-determining region (CDR) or a binding region mimicking such as binding region, allowing binding to a prion protein or part thereof) specifically reactive with a neo-epitope which is exposed on a part of an aberrant conformer (PrP^{Sc}) of a prion protein after treatment of said conformer with a protease wherein said epitope is not or only partly present or exposed on a prion
10 protein which has not been treated with a protease. Such an antibody as provided by the invention is for example characterized by a higher affinity to said part of said conformer PrP^{Sc} than to a non-aberrant cellular prion protein (PrP^C), in particular when said PrP^{Sc} has been treated with a protease, such as the commonly used protease K, or with pronase.

15 The invention describes for example the exposure of neo-epitopes on scrapie-associated prion protein (PrP^{Sc}) after protease digestion, as well as preparation of antibodies against these epitopes. Antibodies, or other proteins, or compounds specifically reacting with neo-epitopes as described can be used for detection of PrP^{Sc} in tissue or biological fluid samples. Hence, this invention provides new inroads for diagnosis of TSE in animal and
20 human prion diseases.

The present invention demonstrates the presence of neo-epitopes on the infectious form of the prion protein, that is PrP^{Sc}, upon proteolytic degradation by PK.

In a preferred embodiment, the invention provides an antibody wherein said epitope comprises a peptide with an amino acid sequence QXXKXS. Such an antibody is in
25 general broadly reactive with aberrant prion proteins from various mammalian species. It is for example preferred that an antibody according to the invention comprises a specific reactivity to overlapping oligo-peptides derived from the human, ovine, murine as well as hamster PrP amino-acid-sequences that correspond to the bovine PrP amino acid sequence at about amino acid position 108-119, as for example determined in Pepscan
30 analyses with overlapping 15-mer oligo-peptides derived from said amino acid sequences as showed herein in the detailed description (Figure 4). Such analyses can however also be done with smaller or longer oligomers, such as for example 11, 12, 13, 14, 16, 17, or 18

-mers. It is preferred that said bovine PrP amino acid sequence comprises GQWNKPSKPKTN. Central to the present invention is the unexpected finding that neo-epitopes are exposed on PrP^{Sc} upon cleavage by protease K. As an example, it is shown that a particular monoclonal antibody (Mab 1E4), raised against a peptide covering the
 5 AA sequence GQWNKPSKPKTN of the bovine PrP (AA₁₀₈₋₁₁₉), binds to PK-digested PrP^{Sc} with a high affinity, whereas it has a low affinity for non-digested PrP^{Sc}. The affinity of Mab 1E4 for PrP^C is even lower than for non-digested PrP^{Sc}.

Antibodies against these epitopes are exemplified by a monoclonal antibody (Mab) which is derived or derivable from hybridoma cell 1E4 deposited with COLLECTION
 10 NATIONALE DE CULTURES DE MICRO-ORGANISMES (CNCM) Institut Pasteur 28, rue du Dr Roux 75724 PARIS Cedex 15 France on July 3 2002 under accession number CNCM I-2906 constitute suitable reagents to detect PrP^{Sc} in biological materials. As antibody, several kinds of binding molecules may be used. For example specific phage-display generated binding peptides are also provided. As a coding sequence for such binding
 15 peptides, the invention provides a nucleic acid sequence encoding the amino acid sequence AGDNDAEDY. It is preferred that an antibody according to the invention comprises a V_H region encoded by a nucleic acid comprising at least a CDR3 having a nucleic acid sequence encoding the amino acid sequence AGDNDAEDY.

The present invention also provides a method to raise antibodies against said neo-
 20 epitopes, and describes the use of these antibodies in assays for PrP^{Sc}.

The invention provides a method for determining the presence of a prion protein in a biological sample via the detection of a complex between said protein and said antibody, said method comprising: contacting a biological sample with an effective amount of antibody according to the invention, under conditions suitable for the formation of said
 25 complex, and detecting said complex as indicative of the presence of a prion protein. In a preferred embodiment, the invention provides a method for determining the presence of a prion protein in a biological sample, wherein said method comprises immobilization of proteins present in the sample on a support surface, contacting the sample with a diagnostically effective amount of antibody according to the invention under conditions
 30 such that a complex forms between said antibody and said protein and detection of said complex. Furthermore, proteins present in the sample can also be immobilized on various surfaces, such as for example on a polyvinylidene difluoride (PVDF) membrane in a

Western-blot analysis or, as another example, on the surface of a microtitre plate in an ELISA-type assay. A suitable method as provided herein (Figure 1) comprises testing for aberrant prions in biological material, for example via an immuno-blotting procedure in which PK-digested prion-containing material is separated, e.g. by sodium dodecyl sulphate polyacrylamide gel-electrophoresis (SDS-PAGE), transferred onto sheets consisting of PVDF or other material, and incubated with a labelled antibody or binding molecule according to the invention that is directed against said prion protein. PrP^{Sc} is discriminated from PrP^C, because of its lower apparent molecular weight after PK digestion. Where the antibodies that are in general used for this procedure do not discriminate between PrP^{Sc} and PrP^C per se, the discrimination is usually made because of the different migration pattern of PK-resistant prion protein on SDS-PAGE. As the present invention shows the existence of neo-epitopes exposed on protease-cleaved prion, antibodies, or other proteins or binding molecules preferentially binding to these neo-epitopes, are superior in detecting PrP^{Sc} since they will not or to a limited extent bind to PrP^C present in the sample.

In a preferred embodiment, the type of support surface is a nitrocellulose membrane, as for example shown herein in the detailed description of a spot-blot analysis of BSE-infected brain of cattle using an antibody according to the invention (Figure 2). This analysis shows that said antibody has a low affinity for bovine PrP^C and PrP^{Sc}, but a substantially higher affinity for PrP²⁷⁻³⁰ as compared to a more conventional PrP antibody.

In another preferred embodiment, a method is provided for determining the presence of a prion protein in a biological sample comprising at least mixing of said sample in solution with a diagnostically effective amount of antibody according to the invention under conditions such that a complex forms between said antibody and said protein; detecting said complex; and comparing the amount of complex formed with an amount formed when the steps are separately performed using a control sample in place of a biological sample. The invention can for example be used for a direct or a competitive ELISA-type assay.

In yet another preferred embodiment, the invention provides a method for determining the presence of a prion protein in a biological sample comprising at least immobilizing an antibody according to the invention on a support surface, contacting said

sample with said antibody under conditions such that a complex forms between said antibody and said protein; and detecting said complex. For example, the antibody can be covalently attached to a solid phase material that can for example be used for chromatographic procedures. Another example is immobilization of said antibody on a sensor chip surface for real time biomolecular interaction analysis (BIA) based on surface plasmon resonance (SPR). Advantageously, the invention provides a method comprising coating the surface of a microtiter plate with an antibody according to the invention, which can then be used for an ELISA-type assay.

As said, the invention provides a method for determining the presence of a prion protein in a biological sample via the detection of a complex between said protein and an antibody according to the invention. Detection of said complex can be performed by various means. A particular means of detection is the measurement of luminescence, as described herein in the detailed description of a Western blot analysis (Figures 1 and 3) or a spot-blot assay (Figure 2), comprising detection of bound antibodies using a HRP-conjugate and enhanced chemiluminescence (ECL) as substrate. Furthermore, the invention also provides a method wherein said complex is detected by other means such as for example a colorimetric, a fluorescent, a radioactive, an electrical or a magnetic measurement. The invention provides for a diagnostic kit to detect the presence of a prion protein in a biological sample using an antibody according to the invention. As described above, an antibody can be used for various procedures to detect the presence of a prion protein in a biological sample via the detection of a complex between said protein and said antibody, such as for example an ELISA-type assay, a Western blot or an immuno-histochemical assay. In a preferred embodiment, a diagnostic kit contains means for performing a dot-blot assay using an antibody according to the invention to detect the presence of a prion protein in a biological sample.

The present invention also provides a method to raise antibodies against neo-epitopes exposed upon protease-cleavage of PrP^{Sc}. A set of cells of antibody-producing cells is obtained by conventional hybridoma technology known in the field. A mouse is immunised with a prion-protein peptide. Lymphocytes are taken from the spleen and fused to myeloma cells. Hybrid cells are selected and individual hybrid cells are cultured for several days. Aliquots of the culture supernatants are removed and tested for the presence of a monoclonal antibody that reacts with PrP^{Sc} protein via the detection of a

complex between said antibody and said protein. Subsequently, an antibody is selected for their ability to react stronger with protease-digested PrP^{Sc} material compared to non-digested PrP^{Sc} to enrich for antibodies against neo-epitopes exposed upon digestion of PrP^{Sc}. Preferably, a selected antibody has at least a six-fold higher affinity for digested PrP^{Sc} than for the non-digested PrP^{Sc}. As shown in Figure 2, a spot-blot analysis can be used to screen for monoclonal antibodies against neo-epitopes exposed upon digestion of PrP^{Sc}, comprising immobilizing serial dilutions of protease-treated or crude brain homogenates derived from normal and infected cattle onto nitrocellulose membrane, drying and blocking said membrane and contacting said membrane with monoclonal antibody supernatants. Bound antibodies can be detected using goat-anti-mouse-immunoglobulin HRP conjugate and ECL as substrate. Clones are selected which produce a monoclonal antibody that is a relatively high affinity for digested PrP^{Sc} and a relatively low affinity for non-digested PrP^{Sc} and for both the digested and non-digested forms of PrP^C. Furthermore, an antibody selection procedure may involve phage display technology which is well known in the field of recombinant antibody production. A host mammal is immunized with PrP protein to mount an immune response. Cells responsible for the production of PrP antibodies are extracted and mRNA is isolated. A cDNA library is produced by reverse transcription of the RNA. Gene fragments encoding V_H and V_L are amplified and assembled into a single gene using a DNA linker through PCR. The recombinant DNA fragments can be inserted into a phage display vector such that antibodies are expressed on the phage to obtain a single-chain Fab library. Use of a general panning protocol, involving repeated rounds of sequential binding, washing, elution and reinfection, allows for the selection of antibodies against an antigen. An antigen can be a protein, such as a prion protein. An antigen can also be a synthetic peptide, for example a peptide with an amino acid sequence that corresponds to a prion protein such as PrP^{Sc}. Preferably, said peptide is an epitope of protease-digested PrP^{Sc} that is not available on non-digested PrP^{Sc}.

Advantageously, a selected antibody is characterized by a low affinity for both the digested and the non-digested forms of the non-aberrant cellular prion protein PrP^C. In contrast to prion-protein antibodies described so far, an antibody selected according to the invention is highly suitable for immunodiagnostic purposes because it does not detect the high background of PrP^C that is observed in general and in blood in particular. The

invention provides a method to generate an antibody with a specific reactivity to the amino acid sequences that correspond to the bovine PrP amino acid sequence GQW NKPSKPKTN comprising immunoscreening by ELISA carried out according to established Pepscan procedures. Furthermore, said antibody is preferably characterized
5 by a second specific interaction site with mouse and/or hamster PrP at the amino acid sequence corresponding to the murine amino acid position 217-222. As shown herein (Figure 4), it is preferred that a selected antibody has a specific reactivity to overlapping 15-mer oligopeptides derived from murine as well as hamster PrP amino acid sequence that correspond to murine PrP amino acid sequence at about amino acid position 217-222
10 in Pepscan analysis.

In a preferred embodiment, a method according to the invention provides an antibody having a high affinity for PrP of a broad range of species, comprising testing a set of antibodies for reactivity of said antibody with oligomerpeptides derived from the human, bovine, ovine, murine and hamster PrP in Pepscan analysis. Such a broadly
15 reactive antibody is suitable as a general antibody for determining the presence of a prion protein in a biological sample, and can be used for the diagnosis of BSE, scrapie or CJD.

The invention is further described in the detailed description.
20

Figure legends

Figure 1

Western blot analysis of BSE-infected brain of cattle using Mabs 1E4 and 6H4 (Prionics AG) demonstrating a neo-epitope on PK-digested PrP^{Sc}. 10% brain homogenates of BSE infected and normal cattle were treated with and without PK and 3-fold serial dilutions were prepared and loaded to two 12% PAA NuPage gels. After electrophoresis and blotting to polyvinylidene difluoride (PVDF) membrane, one blot was stained with Mab 1E4 (upper panel) and one with 6H4 (lower panel). Lanes 1, 9: empty; lane 2: Prionics kit control (1% brain homogenate of normal cattle); lanes 3-8: 3-fold serial dilution of 10% brain homogenate treated with PK; lanes 10-15: 3-fold serial dilution of 10% brain homogenate without PK treatment; lanes 16 and 17: 10% brain homogenate of normal cow without and with PK treatment.

Figure 2

Spot-blot analysis of BSE-infected brain of cattle using Mabs 1E4 and 6H4. 10% brain homogenates of BSE-infected and normal cattle were treated with and without PK and 3-fold serial dilutions were prepared in SDS-sample buffer and spotted to NC, one membrane was stained with Mab 1E4 (left panel) and one with 6H4 (right panel).

Figure 3

Western blot analysis of variant- and sporadic-CJD infected human (vCJD/sCJD). 10% brain homogenates of vCJD and sCJD patient and normal human were treated with and without PK and loaded to a 12% PAA NuPage gel. After electrophoresis and blotting to PVDF membrane, the blot was stained with Mab 1E4. Lanes 1, 3: vCJD; lanes 4, 6: sCJD (type 1); lanes 9, 11: sCJD (type 2); lanes 12 and 14, normal human; lanes 1, 4, 9, and 12: not treated with PK; lanes 3, 6, 11, and 14: treated with PK; lanes 2, 5, 10, and 13: empty.

Figure 4

Pepscan analysis of Mab 1E4. The reactivity of Mab 1E4 to 15-mer oligo-peptides derived from the human, bovine, ovine, murine and hamster PrP amino-acid (AA)-sequences was

measured. Mab 1E4 binds specifically to the AA-sequences homologous to the bovine PrP₁₀₈₋₁₁₉ region and share the QW NKPS as core AA-sequence. Moreover an AA-sequence homologous to that of the epitope appears to be present in mouse and hamster PrP₂₁₇₋₂₂₂ region implying the AA Q109, K112 and S114 to be essential in the epitope for Mab 1E4
 5 in the linear sequence QXXKXS.

Figure 5

Summary of pepscan data of Mab 1E4 and other anti-PrP Mabs; P4, 2D6, 3F4, KG9, 6H4. Mab 1E4 was the only monoclonal antibody that reacted with all species tested.

10

Figure 6

Multiple amino acid alignment of PrP of the most important animal species. Residues different from sheep PrP are boxed. Numbering is according to sheep PrP. Above the alignment a schematic representation is shown of the various regions or domains within prion proteins (PrPC). Structural element boundaries as determined by homology
 15 modeling (Swissmodel, Peitsch, 1996) of sheep PrP on basis of hamster and mouse structural data. Putative glycosylation sites (CHO) as well as octarepeat regions (R), alpha-helices (H), beta-sheets (S), and the disulphide bonds (S-S) are indicated separately (alpha-helices and beta-sheets only account for PrPC). The Proteinase-K cleavage site in
 20 PrP^{Sc} (conformational structure dependent) is indicated at region 82-94.

Detailed Description

Here we describe the exposure of neo-epitopes by PrP^{Sc} upon cleavage by PK. These neo-epitopes can be used to identify a novel class of binding molecules for the detection of prions in tissues containing high concentrations of PrP^C. This class is exemplified by the isolation and characterisation of a new monoclonal antibody (1E4) that has a low affinity for the PrP^C and undigested PrP^{Sc} as compared to its affinity to PK-digested PrP^{Sc} the so-called PrP²⁷⁻³⁰ [the 27-30 kD fragment of PrP^{Sc} obtained after PK-digestion]. The remarkable specificity of this antibody was found upon analysis of a series of antibodies generated against PrP-derived peptides mapped very close to the N-terminal end of PrP²⁷⁻³⁰. The new class of binding proteins will improve the detection of prion in several species including human, bovine, ovine, and murine, as is indicated by showing examples of application of this class of binding molecules in various test systems, including Western blotting, and immuno-histochemistry. Furthermore, we will show examples of using these molecules for strain typing within and between species. As an example of this approach we will describe the selection, isolation and characterisation of Mab 1E4.

Examples

Isolation of monoclonal antibody 1E4

Monoclonal antibody 1E4 was isolated from fusion of spleen cells of a Prnp^{0/0} mouse, immunised with the peptide GQWNKPSKPKTN# (corresponding to the bovine PrP AA sequence 108-119; #=amidated carboxy-terminus) coupled to KLH at its N-terminal end via a CG-AA linker. Sera from 6 out of 10 mice immunised with this KLH-coupled peptide reacted positive in scrapie/BSE dot-blot assay. Moreover sera from two mice contained high titers of antibodies as detected in anti-peptide ELISA and radio-immunoassay (RIA), detecting immobilised and fluid phase interaction, respectively. One of these mice was selected for fusion. Four days after a final boost with the KLH-coupled peptide, the spleen was collected, and spleen cells were isolated and fused with SP2/0-Ag14 myeloma cells. The fused cells were plated in 96-well plates at a density of 10⁵ cells/well. After 7 and 14 days of selection with HA (hypoxanthine and azaserine), culture supernatants were screened for specific antibodies with the anti-peptide RIA, resulting in

23 positive wells. Limiting dilution of these clones revealed that only 10 clones were stable regarding IgG production as measured with the anti-peptide RIA. The cells from these 10 wells were subsequently subcloned three times by limiting dilution. Each subcloning step was monitored with the anti-peptide RIA, ultimately resulting in five stable clones. Culture supernatant of clone 1E4 was tested with Western blot demonstrating a strong binding reaction to BSE brain homogenates treated with PK, whereas virtually no binding was found to brain homogenates from healthy controls. This observation showed the unique binding characteristic on the 1E4 monoclonal antibody that was subsequently analysed in detail.

Characterisation of monoclonal antibody 1E4

The binding properties of Mab 1E4 were compared with those of generally used Mab 6H4 (Prionics AG, Zürich, Switzerland) using Western blot. BSE samples were treated with PK and subsequently three-fold serial dilutions of the samples were prepared. Mab 1E4 still yielded a positive reaction with a 243-fold dilution of the PK-treated sample, whereas the 81-fold dilution of the untreated sample was found negative (Figure 1). Using Mab 6H4 the 81-fold dilutions of both PK-treated and untreated BSE samples was found positive. Therefore this Western blot indicates that 1E4 has at least a nine-fold higher affinity for the PK-digested BSE sample as compared to untreated sample, assuming that 6H4 has a similar affinity for both types of antigens. This pivotal observation suggests that 1E4 has a higher affinity for the cleaved PrP²⁷⁻³⁰ than for the non-cleaved PrP^{Sc}. Moreover the Western blot also included a brain homogenate sample derived from a normal cow. Mab1E4 reacted only weakly with the latter sample, whereas 6H4 reacted very strongly with the sample suggesting that 1E4 has at least a nine-fold lower affinity for PrP^C than 6H4 has. So compared to 6H4, 1E4 has a lower affinity for PrP^C and PrP^{Sc}, but a higher affinity for PrP²⁷⁻³⁰.

These differences in affinity for PrP^C, PrP^{Sc}, and PrP²⁷⁻³⁰ were more striking using a spot-blot assay (Figure 2). Using Mab 1E4 the 270-fold dilution of the PK-treated BSE sample was found positive, whereas the 10-fold dilution of the untreated sample was found negative. Using Mab 6H4 however the 90-fold dilution of the PK-treated BSE sample was positive, whereas the 810-fold dilution of the untreated sample was found positive.

Furthermore Mab 1E4 did not react with brain homogenate derived from a normal cow, whereas Mab 6H4 reacted with the 2430-fold dilution of the sample. These findings confirm that 1E4 has a lower affinity for bovine PrP^C and PrP^{Sc}, but a higher affinity for PrP²⁷⁻³⁰ as compared to 6H4.

5

Mab 1E4 also reacted with prion from 301V-infected mice, scrapie-infected sheep and sCJD- and vCJD-infected human using Western blots (Figure 3). However the striking difference between the affinity for cleaved and non-cleaved PrP^{Sc} observed for BSE in cattle is not seen in these samples.

10

The broad species reactivity in the Western blot is also seen on the Pepscan analysis of Mab 1E4. As already indicated the antibody originated from a mouse immunised with KLH-cg-Bovine PrP₁₀₈₋₁₁₉; the AA-sequence was GQW NKPSKPKTN# and Pepscan analysis showed a linear epitope for Mab 1E4 present in this AA region in bovine, sheep, human, mouse and hamster with QW NKPS as core AA sequence (Figure 4). Furthermore a mimic of the epitope was found on mouse and hamster PrP₂₁₇₋₂₂₂ (AA sequence QYQKES) implying the AA Q109, K112 and S114 to be essential residues for antibody binding in the original epitope for Mab 1E4. Replacement analysis of PrP₂₂₀ AA K by R, as it is present by bovine, sheep and human, resulted in absence of binding activity to mouse and hamster in the Pepscan in this region.

20

When we compared 1E4 with other PrP Mabs in Pepscan analysis, 1E4 appeared to be the only antibody having high affinities for a broad range of species (Figure 5). Therefore the antibody would be suitable as a general antibody for detection prions in general and for BSE in particular. The broad species reactivity of Mab 1E4 is also found when the antibody is used for immuno-histochemistry of sections from brainstem of BSE-infected cattle, brainstem of BSE- and scrapie-infected sheep, and total brain of BSE- and scrapie-infected mice.

25

To further characterise the immunoglobulin that is produced by clone 1E4, we RT-PCR-cloned the V_H region of the Ig expressed by clone 1E4. The amplified cDNA was

30

sequenced and the hypervariable CDR3 region was identified. The CDR3 AA sequence of clone 1E4 is AGDNDAEDY.

Novel applications using monoclonal antibody 1E4

- 5 The lower affinity for PrP^C, PrP^{Sc}, and higher affinity for PrP²⁷⁻³⁰ was particularly found for BSE-infected cattle, but not e.g. for scrapie-infected sheep. This property of Mab 1E4 might be exploited to facilitate discrimination between BSE and scrapie in sheep and human CJD cases. Hereby we assume that the position of PK-cleavage for prion in sheep with scrapie might differ from that in sheep with BSE. Thus, biochemical differences
- 10 found between TSE strains (scrapie strains of hamster, scrapie of sheep, and BSE of cattle) have been reported. ^{6, 13}

Methods

Monoclonal antibodies

P4, 2D6, 3F4, KG9, 6H4 (Prionics AG). 9, 10, 11, 14, 15

5

Selection and synthesis of peptides

We selected the bovine PrP₁₀₈₋₁₁₉ AA sequence. The selected peptide
cgGQWNKPSKPKTN, corresponding to the bovine PrP AA-sequence 108-119 plus the
additional CG for flexibility and coupling, was synthesised from fmoc AA. Coupling of
10 KLH to the N-terminal side of the peptide was done using a bifunctional linker MBS.

Immunisation

The selected peptide was synthesised and coupled to KLH before immunising a group of
five Prnp^{0/0} mice (Charles Weissmann [Zürich, Switzerland]). Mice were immunised
15 intraperitoneally using 30 µg of peptide suspended into Freund's Incomplete
Adjuvans/PBS. Mice were boosted at 19, 59, and 136 days post immunisation (dpi).

Screening of mice sera

Sera of the mice were collected at 73 dpi and analysed using various immuno-assays. Two
20 different assays were used for detecting the peptide specific responses – anti-peptide
ELISA and anti-peptide RIA -, whereas also assays were used to detect responses
against PrP^C (PrP^C ELISA) and PrP^{Sc} (Scrapie/BSE dot-blot)

Anti-peptide ELISA

25 ELISA plates were coated with BSA-coupled peptide and incubated with various
dilutions of mice sera that were collected at -7 and 73 dpi. Bound antibodies were
detected using a goat-anti-mouse-HRP conjugate and using TMB as a substrate.

Anti-peptide RIA

30 Radiolabelled BSA-coupled peptide (¹²⁵I-peptide, iodogen method) was incubated with
mice sera. Subsequently bound and free-labelled peptide was separated by addition of

rat-anti-mouse-immunoglobulin coupled Sepharose, incubation and centrifugation. Gamma counter quantified radioactivity in the pellet.

PrPC ELISA

- 5 ELISA plates were coated with normal bovine or ovine crude brain homogenate and incubated with various dilutions of mice sera that were collected at -7 and 73 dpi. Then the bound antibodies were detected using a goat-anti-mouse-immunoglobulin-HRP conjugate and using TMB as a substrate.

10 *Scrapie/BSE dot-blot assay*

- Strips of PVDF membrane were spotted with PK-treated crude brain homogenate derived from normal sheep, scrapie-infected sheep, normal cattle and BSE-infected cattle. Samples were diluted three-fold and nine-fold and 3 µl spots were applied in duplicate. Subsequently the strips were incubated with various dilutions of mice sera that were
15 collected 7 days before immunisation and 73 dpi. Bound antibodies were detected using a goat-anti-mouse-immunoglobulin-HRP conjugate, enhanced chemiluminescence as substrate, and visualised using NBT, BCIP as substrate.

Fusion of spleen cells and preparation of Mab

- 20 Four days after the final booster, spleen cells of a selected mouse were fused with SP2/0-Ag14 myeloma cells in a 3:1 ratio and were plated in 96-well cluster plates (density 10^5 cells/well). Hybridoma culture supernatants were screened for presence of specific antibodies by anti-peptide RIA and Scrapie/BSE dot-blot assay one and two weeks later.

25 *Selection and subcloning of Mab*

- Clones giving positive results in both anti-peptide RIA and scrapie/BSE dot-blot assays were subcloned three times by limiting dilution. Anti-peptide RIA was used to monitor production of specific antibodies during the cloning steps.

Characterisation of Mab

After three limiting dilution subcloning cycles, the finally selected clones were characterised using Western blotting, spot-blotting, pepscan, immuno-histochemistry, and CDR3.

5

Western blotting

Western blotting was carried out according to the Prionics Check kit specifications (Prionics AG). Briefly, proteins present in PK-treated or crude brain homogenates derived from normal sheep, scrapie infected sheep, normal cattle and BSE infected cattle were first separated on SDS-12.5% polyacrylamide gels and blotted on PVDF
10 membranes. Subsequently the membranes were incubated with selected Mab supernatants. Bound antibodies were detected using a goat-anti-mouse-HRP conjugate, enhanced chemiluminescence as substrate, and visualised by exposure to ECL hyperfilm.

Spot-blot

Protease-K-treated or crude brain homogenates derived from normal sheep, scrapie infected sheep, normal cattle and BSE infected cattle were diluted three-fold and nine-fold and 5 µl spots were applied to a nitrocellulose membrane. After drying and blocking the membranes were incubated with selected Mab supernatants. Bound antibodies were
20 detected using a goat-anti-mouse-immunoglobulin HRP conjugate, enhanced chemiluminescence as substrate, and visualised by exposure to ECL hyperfilm.

Pepscan

Solid phase synthesis of peptides on polyethylene pins and immunoscreening by ELISA were carried out according to established PEPSCAN™ procedures.^{18, 19} Complete sets
25 were synthesised of overlapping 15-mer peptides in 3 µl polyethylene wells, covering the amino sequences of human, bovine, ovine, murine and hamster PrP and binding of antibodies to these sets was determined.^{20, 21, 22, 23, 24}

Immuno-histochemistry

Tissues were collected and embedded in paraffin and sections were cut, and stained with 1E4 (1:10 dilution).²⁵

30

CDR3 determination

The V_H region of clone 1E4 was RT-PCR amplified using primers as described by Dattamajumdar et al. (1996).²⁶ The amplified PCR product was purified and used for sequence analysis.

References

- 1 Prusiner SB, Prions (1998). PNAS 95, 13363-13383.
- 10 2 Wadsforth JDF et al., Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay (2001). Lancet 358, 171-180.
- 3 Schreuder BE et al., Preclinical test for prion diseases (1996). Nature 381, 563.
- 4 Naslavsky N, et al., Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform (1997). JBC 272, 6324-6331.
- 15 5 Wiessmann C, The ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies (1996). FEBS Letters 389, 3-11.
- 6 Safar J et al., Eight prions strains have PrP^{Sc} molecules with different conformations (1998). Nature Medicine 4, 1157-1165.
- 20 7 Schmerr MJ and Jenny A, A diagnostic test for scrapie-infected sheep using a capillary electrophoresis immunoassay with fluorescent-labeled peptides (1998). Electrophoresis 19, 409-413.
- 8 Houston F et al. Transmission of BSE by blood transfusion in sheep (2000). Lancet 356, 999-1000
- 25 9 Kascsak RJ et al., Mouse polyclonal and monoclonal antibody to scrapie-associated fibrin proteins (1987). J Virol 61, 3688-3693.
- 10 Laffling AJ, et al. A monoclonal antibody that enables specific immunohistological detection of prion protein in bovine spongiform encephalopathy cases (2001). Neurosci Lett. 300, 99-102.
- 30 11 Korth C et al., Prion (PrP^{Sc})-specific epitope defined by a monoclonal antibody (1997). Nature 390, 74-77.

- 12 MacGregor I, Prion protein and developments in its detection (2001). *Transf Med* 11, 3-14.
- 13 Madec JV et al., Sensitivity of the Western blot detection of protein PrPres in natural sheep scrapie (1998). *J Virol Method* 75, 169-177.
- 5 14 Harmeyer, S et al., Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants (1998). *J Gen Virol* 79, 937-945
- 15 Garssen GJ et al., Int. Patent application nr. PCT/NL00/00079 (2000). "Prion test".
- 16 Van Keulen LJ et al., Immunohistochemical detection and localization of prion protein in brain tissue of sheep with natural scrapie (1995). *Vet-Pathol.* 32, 299-308.
- 10 17 Garssen GJ et al., A rapid assay for BSE and scrapie. Int. Symp. "Characterization and Diagnosis of Prion Diseases in Animals and Man". Sept. 1999. Tübingen. Germany
- 18 Geysen HM et al., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid (1984). *PNAS* 81, 3998-4002.
- 19 Piccardo P et al., An antibody raised against a conserved sequence of the prion protein recognizes pathological isoforms in human and animal prion diseases, including Creutzfeldt-Jakob disease and bovine spongiform encephalopathy (1998). *Am J Pathol* 152, 1415-1420.
- 15 20 Kretzschmar HA et al., Molecular cloning of a human prionprotein cDNA (1989). *DNA* 5, 315-324.
- 20 21 Goldmann W et al. Different forms of the bovine PrP gene have five or six copies of a short, G-C-rich element within the protein-coding exon (1991). *J Gen Virol* 72, 201-204.
- 22 Goldmann W et al., Two alleles of a neural protein gene linked to scrapie in sheep (1990). *PNAS* 87, 2476-2480.
- 23 Westaway D et al., Distinct prion proteins in short and long scrapie incubation period mice (1987). *Cell* 51,651-662.
- 25 24 Robakis NK et al., Isolation of a cDNA clone encoding the leader peptide of prion protein and expression of the homologous gene in various tissues (1986). *PNAS* 83, 6377-6381.
- 25 Van Keulen LJM et al., Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie (1996). *J Clin Microbiol* 34, 1228-1231.
- 30 26 Dattamajumbar AK et al., Rapid cloning of any rearranged mouse immunoglobulin variable genes (1996). *Immunogenetics* 43, 141-151.

17. 07. 2002

CLAIMS

(83)

- 5 1. An antibody specifically reactive with an epitope which is exposed on a part of an aberrant conformer (PrP^{Sc}) of a prion protein after treatment of said conformer with a protease wherein said epitope is not or only partly exposed on a prion protein which has not been treated with a protease.
- 10 2. An antibody characterized by a higher affinity to an aberrant prion protein (PrP^{Sc}) than to a non-aberrant prion protein (PrP^C).
3. An antibody according to claim 2 wherein said PrP^{Sc} has been treated with a protease.
- 15 4. An antibody according to anyone of claims 1 to 3 wherein said protease comprises protease K.
5. An antibody according to anyone of claims 1 to 4 wherein said epitope comprises a peptide with an amino acid sequence QXXKXS.
- 20 6. An antibody according to anyone of claims 1 to 5 with a specific reactivity to overlapping 15-mer oligo-peptides derived from the human, ovine, murine as well as hamster PrP amino-acid-sequences that correspond to the bovine PrP amino acid sequence at about amino acid position 108-119.
- 25 7. An antibody according to claim 6 wherein said bovine PrP amino acid sequence comprises GQW NKPSKPKTN.
- 30 8. An antibody according to claim 7 comprising a V_H region encoded by a nucleic acid comprising at least a CDR3 having a nucleic acid sequence encoding the amino acid sequence AGDNDAEDY.

9. A hybridoma cell capable of producing a monoclonal antibody of claim 7 or 8.
- 5 10. Hybridoma cell 1E4 having the deposit accession number CNCM I-2906.
11. A method for determining the presence of a prion protein in a sample comprising using an antibody according to anyone of claims 1 to 8.
- 10 12. A method according to claim 11 for determining the presence of a prion protein in a biological sample via the detection of a complex between said protein and said antibody.
13. A diagnostic test kit for the determination of the presence of a prion protein in a biological sample comprising an antibody according to anyone of claims 1 to 8.
- 15 14. A method for obtaining an antibody according to anyone of claims 1 to 8 , comprising :
- providing a set of antibody-producing cells by,
- 20 testing said cells for the presence of an antibody specifically reactive with PrP^{Sc}.
- testing the ability of said antibody to react with higher affinity with PrP^{Sc} than with PrP^C.
- 25 selecting an antibody specifically reactive with protease-digested PrP^{Sc} comprising testing the ability of said antibody to react with higher affinity with protease-digested PrP^{Sc} material compared to non-digested PrP^{Sc} material
- 30 15. A method according to claim 14 further comprising selecting an antibody specifically reactive with PrP from multiple species

16. A method according to claim 15 further comprising testing said antibody for reactivity of said antibody with oligomerpeptides derived from the human, bovine, ovine, murine and hamster PrP.

5

17. A method according to anyone of claims 14-16 further comprising selecting an antibody with an additional reactivity with a peptide with an amino acid sequence QXXKXS comprising measuring the reactivity of said antibody with oligomerpeptides derived from murine as well as hamster PrP amino acid sequence that correspond to
10 murine PrP amino acid sequence at about amino acid position 217-222 in a Pepscan analysis.

15

17. 07. 2002

Title: Detection of prion disease

Abstract

(83)


- 5 This invention relates to the field of the detection of prion diseases. The invention provides a binding molecule or antibody specifically reactive with an epitope which is exposed on a part of an aberrant conformer (PrP^{Sc}) of a prion protein after treatment of said conformer with a protease wherein said epitope is not or only partly exposed on a prion protein which has not been treated with a protease.

figure 1

17. 07. 2002

Western Blot characteristics of clone 1E4 compared with Clone 6H4

(83)



Spotblot characteristics of clone 1E4 compared with Clone 6H4




figure 3

Western Blot characteristics of clone 1E4 on human samples





figure 4

Pepscan of clone 1E4 on PrP of various species



Pepscan of various PrP MAb, reactivity pattern on various species

Immunogen	MAb	Human	Bovine	Ovine	Hamster	Murine
bovine peptide	1E4	+	+	+	+	+
Ovine peptide	P4	-	+	+	-	-
Ovine peptide	2D6	-	-	+	-	+
Hamster PrPsc	3F4	+	-	-	+	-
rec Bovine PrP	KG9	+	+	-	-	-
rec Bovine PrP	6H4	+	+	+	+/-	+/-

figure 6

